Tubing loops as a model for cardiopulmonary bypass circuits: Both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vivo model

Journal of Clinical Immunology

Volumn 16, Issue 4, 1996, Pages 222-229

  Gong, Jian ^a   Larsson, Rolf ^a   Ekdahl, Kristina Nilsson ^a   Mollnes, Tom Eirik ^b   Nilsson, Ulf ^a   Nilsson, Bo ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

C3a; Cardiopulmonary bypass; Complement activation; Heparin; Terminal sC5b 9

Indexed keywords

COMPLEMENT COMPONENT C3A; HEPARAN SULFATE; HEPARIN;

ADULT; ARTICLE; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; ENZYME IMMUNOASSAY; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL;

BIOCOMPATIBLE MATERIALS; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C3A; COMPLEMENT SYSTEM PROTEINS; GLYCOPROTEINS; GLYCOSAMINOGLYCANS; HEPARIN; MATERIALS TESTING; MODELS, ANATOMIC; POLYETHYLENES; TIME FACTORS;

EID: 0029924746     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01541228     Document Type: Article

References (32)

1. Greeley WJ, Ungerleider RM: Assessing the effect of cardiopulmonary bypass on the brain. Ann Thorac Surg 52:417-419, 1991
2. Kirklin JK: The postperfusion syndrome. In Cardiopulmonary Bypass: Current Concepts and Controversies, Tinker JH (ed). Philadelphia, W. B. Saunders, 1989, pp 131-147
3. Oeveren Wv, Kazatchkine MD, Descamps-Latscha B, Haillet F, Fischer E, Carpentier A, Wildevuur CRH: Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. J Thorac Cardiovasc Surg 89:888-899, 1985
4. Westaby S: Organ dysfunction after cardiopulmonary bypass. A systemic inflammatory reaction initiated by extracorporeal circuit. Intens Care Med 13:89-95, 1987
5. Gillinov AM, DeValeria PA, Winkelstein JA, Wilson I, Shaw D, Yen CG, Rudolph AR, Baumgartner WA, Herskowitz A: Complement inhibition with soluble complement receptor type 1 in cardiopulinonary bypass. Ann Thorac Surg 55:619-624, 1993
6. Sims PJ, Wiedmer T: The response of human platelets to activated components of the complement system. Immunol Today 12:338-342, 1991
7. Rinder CS, Rinder HM, Smith BR, Fitch JC, Smith JS, Tracey JB, Matis LA, Squinto SP, Rollins SA: Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 96:1564-1572, 1995
8. Johnson RJ: Complement activation by biomaterials. Prog Clin Biol Res 337:507-512, 1991
9. Pekna M, Nilsson L, Nilsson Ekdahl K, Nilsson UR, Nilsson B: Evidence tor iC3 generation during cardiopulinonary bypass as the result of blood-gas interaction. Clin Exp Immunol 91:404-409, 1993
10. Nilsson B, Svensson K-E, Inganas M, Nilsson UR: A simplified assay for the detection of C3a in human plasma employing a monoclonal antibody raised against denatured C3. J Immunol Methods 107:281-287, 1988
11. Nilsson UR, Storm K-E, Elwing H, Nilsson B: Conformational epitopes of C3 reflecting its mode of binding to an artificial polymer surface. Mol Immunol 30:211-219, 1993
12. Pangburn MK, Müller-Eberhard HJ: Relation of a putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med 152:1102-1114, 1980
13. Pangburn MK, Schreiber RD, Müller-Eberhard HJ: Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the thioester in native C3. J Exp Med 154:856-867, 1981
14. Andersson L-O, Barrowcliffe TW, Holmer E, Johnson EA, Sims GEC: Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 9:575-583, 1976
15. Nilsson L, Storm KE, Thelin S, Bagge L, Hultman J, Thorelius J, Nilsson U: Heparin-coated equipment reduces complement activation during cardiopulmonary bypass in the pig. Artific Organs 14:46-48, 1990
16. Videm V, Svennevig JL, Fosse E, Semb G, Osterud A, Mollnes TE: Reduced complement activation with heparin-coated oxygenators and tubings in coronary bypass surgery. J Thorac Cardiovasc Surg 113:806-813, 1992
17. Mollnes TE, Videm V, Götze O, Harboe M, Oppermann M: Formalion of C5a during cardiopulmonary bypass: Inhibition by precoating with heparin. Ann Thorac Surg 52:92-97, 1991
18. Pekna M, Hagman L, Halden E, Nilsson UR, Nilsson B, Thelin S: Complement activation during cardiopulinonary bypass: Effects of immobilised heparin in a clinical study. Ann Thorac Surg 52:421, 1994
19. Nilsson Ekdahl K, Nilsson B, Pekna M, Nilsson UR: Generation of iC3 on the interphase between blood and gas. Scand J Immunol 35:85-91, 1992
20. Mollnes T, Lea T, Frøland SS, Harboe M: Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against neoantigen on the complex. Scand J Immunol 22:703-710, 1985
21. Kinoshita T: Biology of complement: The overture. Immunol Today 12:291-295, 1991
22. Mellbye OJ, Froland SS, Lilleaasen P, Svennevig J-L, Mollnes TE: Complement activation during cardiopulmonary bypass: Comparison between the use of large volumes of plasma and Dextran 70. Eur Surg Res 20:101-109, 1988
23. Videm V, Fosse E, Mollnes TE, Ellingsen Ø, Pedersen T, Karlsen H: Different oxygenators for cardiopulmonary bypass lead to varying degrees of human complement activation in vitro. J Thorac Cardiovasc Surg 97:764-770, 1989
24. Bhakdi S, Fassbender W, Hugo F, Carreno M-P, Berstecher C, Malasit P, Kazatchkine MD: Relative inefficiency of terminal complement activation. J Immunol 141:3117-3122, 1988
25. Hirsh J: Relationship between dose, anticoagulant effect and the clinical efficacy and safety of heparin. In Heparin and Related Polysacharides, Lane DA, Björk I, Lindahl U (eds). New York, Plenum, 1992, pp 283-296
26. Ekre H-PT, Fjellner B, Hagermark Ö: Inhibition of complement-dependent experimental inflammation in human skin by different heparin fractions. Int J Immunopharmacol 8:277-286, 1986
27. Maillet F, Kazatchkine MD, Glotz D, Fisher E, Rowe M: Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b. Mol Immunol 20:1401-1404, 1983
28. Gadd KJ, Reid KBM: The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum. Biochem J 195:471-480, 1981
29. Law SK, Lichtenberg NA, Levine RP: Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces. J Immunol 123:1388-1394, 1979
30. Cheung AK, Parker CJ, Janatova J, Brynda E: Modulation of complement activation on hemodialysis membranes by immobilized heparin. J Am Soc Nephrol 2:1328-1337, 1992
31. Kazatchkine MD, Fearon DT, Metcalfe DD, Rosenberg RD, Austen KF: Structural determinants of the capacity of heparin to inhibit the formation of the human ampliphication C3 convertase. J Clin Invest 67:223-228, 1981
32. Kazatchkine MD, Fearon DT, Silbert JE, Austen KF: Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J Exp Med 150:1202-1215, 1979